Loading clinical trials...
Loading clinical trials...
Aveir Single-Chamber Leadless Pacemaker Real-World Evidence Post-Approval Study
The purpose of this post-approval study is to evaluate the long-term safety of the single-chamber Aveir VR leadless pacemaker using real-world evidence methods.
This is a non-randomized, multi-center study leveraging real-world evidence methods that merge multiple real-world datasets from Abbott and the Center for Medicare Services to assess Aveir VR leadless pacemaker safety in a large patient population. The results from this study will data to fulfill the Condition of Approval requirements for the Aveir VR device from FDA.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Abbott
Sylmar, California, United States
Start Date
June 21, 2022
Primary Completion Date
February 28, 2034
Completion Date
February 28, 2034
Last Updated
August 20, 2024
2,100
ESTIMATED participants
Aveir VR Leadless Pacemaker System
DEVICE
Lead Sponsor
Abbott Medical Devices
NCT07221682
NCT03008291
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07290595